期刊文献+

PD-L1在结直肠癌组织中的表达及临床意义 被引量:8

Expression of PD-L1 and its clinical significance in colorectal cancer
下载PDF
导出
摘要 目的:观察程序性死亡配体-1(PD-L1)在结直肠癌组织及癌旁组织中的表达,探索其与患者临床病理特征之间的相关性,并探讨PD-L1表达水平在结直肠癌中的临床意义。方法:选取2016年1月至2017年1月温州医科大学附属第一医院50例结直肠癌患者,手术中获取癌组织及癌旁组织,采用PCR及Western blot检测结直肠癌及癌旁组织中PD-L1 mRNA及蛋白水平,并分析其与临床病理特征之间的相关性。结果:与癌旁组织相比,结直肠癌组织中PD-L1基因及蛋白表达量均显著升高(P<0.05)。癌组织中PD-L1蛋白阳性率与癌组织分化程度和淋巴转移相关(P<0.05)。结论:PD-L1在结直肠癌组织中表达增高,并与结直肠癌患者的临床病理特征密切相关。 Objective:To investigate the expression of PD-L1 in colorectal cancer and its relationship with clinicopathologic features,and meanwhile to discuss the clinical significance of PD-L1 expression.Methods:Colorectal cancer tissues and adjacent normal tissues were obtained from 50 patients with colorectal cancer.RTPCR and Western blot were conducted to detect the expression of PD-L1 in mRNA and protein levels.Results:The expression of PD-L1 in colorectal cancer tissues was elevated,compared with that in adjacent normal tissues(P<0.05).The elevated expression of PD-L1 in colorectal cancer tissues was correlated with cancer differentiation degree and lymphatic metastasis(P<0.05).Conclusion:PD-L1 was highly expressed in colorectal cancer patients,which was correlated with the clinicopathologic features.
作者 杜舟 黄萍 黄国裕 韩少良 左志贵 DU Zhou;HUANG Ping;HUANG Guoyu;HAN Shaoliang;ZUO Zhigui(Department of Hernia and Abdominal Wall Surgery,the First Affiliated Hospital of Wenzhou Medical University,Wenzhou 325015,China;Office of Development and Planning,Wenzhou Medical University,Wenzhou 325035,China;Department of Gastrointestinal Surgery,the First Affiliated Hospital of Wenzhou Medical University,Wenzhou 325015,China;Department of Colorectal Anal Surgery,the First Affiliated Hospital of Wenzhou Medical University,Wenzhou 325015,China)
出处 《温州医科大学学报》 CAS 2020年第1期41-44,共4页 Journal of Wenzhou Medical University
基金 温州市公益性科技计划项目(2017Y1031)
关键词 结直肠癌 程序性死亡配体-1 癌旁组织 免疫逃逸 colorectal cancer programmed deathligand 1 adjacent normal tissue immune response
  • 相关文献

参考文献6

二级参考文献105

  • 1Fong Y,Fortner J,Sun RL,et al.Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer:analysis of 1001 consecutive cases.Ann Surg,1999,230(3):309-318.
  • 2Minagawa M,Makuuchi M,Torzilli G,ct al.Extension of the frontiers of surgical indications in the treatment of liver motastases from colorectal cancer:long-term results.Ann Surg,2000,231(4):487-499.
  • 3Vauthey JN,Pawlik TM,Abdalla EK,et al.Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg,2004,239(5):722-732.
  • 4Scheele J,Stang R,Ahendorf-Hofmann A,et al.Resection of colorectal liver metastases.World J Surg,1995,19(1):59-71.
  • 5Pawlik TIM,Scoggins CR,Zorzi D,et al.Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases.Ann Surg,2005,241(5):715-724.
  • 6Adam R,Delvart V,Pascal G,et al.Rescue surgery for unresectable colorectal liver metastases dowustaged by chemotherapy:a model to predict long-term survival.Ann Surg,2004,240(4):644-657.
  • 7Petrewsky H,Gonen M,Jarnagin W,et al.Second liver resections are safe and effective treatment for recurrent hepatic metastases from colerectal cancer:a bi-institutional analysis.Ann Surg,2002,235(6):863-871.
  • 8Kanemitsu Y,Kato T,Hirai T,et al.Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer.Br J Surg,2004,91(1):112-120.
  • 9Pozzo C,Basso M,Cassano A,et al.Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients.Ann Oncol,2004,15(6):933-939.
  • 10Folprecht G,Grothey A,Alberts S,et al.Neoadjuvant treatment of unresectable colorectal liver metastases:correlationbetween tumour response and resection rates.Ann Oncol,2005.16(8):1311-1319.

共引文献143

同被引文献81

引证文献8

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部